You are here

Australian Influenza Vaccine Committee (AIVC)

4 September 2020

Role of the AIVC

The Australian Influenza Vaccine Committee (AIVC) provides advice to the Therapeutic Goods Administration (TGA) on the composition of the seasonal influenza vaccine to be supplied each year in Australia.

The meeting is held annually following the September World Health Organisation (WHO) strain consultation meeting, which makes a decision on vaccine composition for the Southern Hemisphere. At the meeting the committee reviews and evaluates current available data related to the epidemiology, antigenic and genetic analysis of recent circulating regional and southern hemisphere influenza isolates and serological responses to the previous season vaccines.

AIVC is not involved in any decision making process under the Therapeutic Goods Act 1989.

Australian Influenza Vaccine Committee (AIVC) members

The following are independent 'voting' members:

  • Professor Robert Booy is Head of the Clinical Research team at the National Centre for Immunisation Research and Surveillance (NCIRS). He is a medical graduate of the University of Queensland (1984) and trained in Paediatrics at the Royal Children's Hospital, Brisbane. Over the past 10 years, Professor Booy has been increasingly recognised as an expert in the influenza field, supervising many studies addressing the burden and prevention of influenza disease in children and adults in the UK, Australia and among Muslim pilgrims to Saudi Arabia. In addition he has led intervention studies with new vaccines, new vaccine delivery methods and alternate methods for preventing disease and transmission such as antivirals and personal protective equipment.
  • Professor Katherine Kedzierska is currently an NHMRC Senior Research Fellow and Laboratory Head in the Department of Microbiology and Immunology at University of Melbourne at the Peter Doherty Institute for Infection and Immunity. Her research interests include human T cell immunity to pandemic, seasonal and newly emerged influenza viruses, anti-viral immunity in the young, the elderly and Indigenous Australians, viral escape and generation of immunological memory in human influenza infection.
  • Associate Professor Helen Marshall is Associate Professor in Vaccinology, in the School of Paediatrics and Reproductive Health and Robinson Research Institute at the University of Adelaide and is the Medical Director of VIRTU, the Vaccinology and Immunology Research Trials Unit, at the Women's and Children's Hospital. She has a Bachelor of Medicine and Surgery, Doctorate of Medicine, Master in Public Health, Diploma in Child Health and a graduate of the Advanced Vaccinology Course, Pasteur Merieux Institute, France.

The following Directors of the WHO National Influenza Centres in Australia are ex-officio 'voting' members:

  • Professor Dominic Dwyer is a medical virologist and infectious diseases physician based at Westmead Hospital and the University of Sydney. He is Director of Public Health Pathology in New South Wales Health Pathology and Director of New South Wales Health Pathology’s Institute of Clinical Pathology and Medical Research. He leads the WHO National Influenza Centre located at the Institute of Clinical Pathology and Medical Research (ICPMR). He has a clinical and research interest in viral diseases of public health importance, including COVID-19, influenza and other respiratory viruses, HIV, antiviral drug resistance and arboviruses. He is actively involved in investigations of outbreaks of viral infections, including at mass gatherings and closed environments.
  • Dr Mike Catton has had a 27-year career as a consultant clinical virologist; the last 20 years as the Victorian Infectious Diseases Reference Laboratory (VIDRL); since 2014 a part of The Peter Doherty Institute For Infection and Immunity, of which he is Deputy Director. His professional interests are in molecular viral diagnostics, high containment laboratory facilities and emerging viruses. Oversight of surveillance, outbreak investigations and capacity development related to viruses of public health significance comprises a significant proportion of his clinical practice. He personally heads national reference laboratories for measles and rubella, viral haemorrhagic fevers and smallpox, a WHO Regional Reference Laboratory for measles, and a WHO National Influenza Centre, and has oversight of WHO Regional Reference Laboratories in poliovirus, and hepatitis B and WHO Collaborating Centres for influenza, viral hepatitis and Mycobacterium ulcerans reporting through others. He has been a member of AIVC since 1996.
  • Professor David Smith is a Medical Microbiologist/Virologist at PathWest Laboratory Medicine WA and a Clinical Professor in the School of Medicine at the University of Western Australia. PathWest provides diagnostic testing to the community and hospitals, reference testing, and public health services. Prof Smith has served on a number of state, national and international committees and advisory groups, including those advising on pandemic and non-pandemic influenza, and he served two terms as Chair of the national Public Health Laboratory Network. He has a particular interest in public health issues, including influenza and other respiratory viruses, mosquito-borne viruses, emerging infections, new diagnostic technologies, and laboratory-based surveillance.

Non-voting ex-officio members are:

  • the Director and Deputy Director of the WHO Collaborating Centre for Reference and Research on Influenza;
  • the Directors of the WHO National Influenza Centres in New Zealand and South Africa;
  • four officers of the Department of Health nominated by the Chief Medical Advisor (CMA) of the TGA, one of whom will also be nominated as the Chairperson.

AIVC meeting dates

  • 7 October 2020

Contacting AIVC

Fax +61 2 6203 1250
Postal address Australian Influenza Vaccine Committee
Therapeutic Goods Administration
PO Box 100
Woden ACT 2606
Attn: Scheduling & Committee Support Section, MDP 122